glp-1 digital health platforms startups companies are launching programs around GLP-1s 9 Companies Developing Next-Generation GLP-1

doi:10.3109/00498259309059412

Everyone must follow the Wegovy dosing schedule, as it can reduce the risk of side effects

For instance, in November 2023, results from the SELECT trial published in the New England Journal of Medicine showed that once-weekly semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease without diabetes, highlighting the expanding role of long-acting GLP-1 analogues beyond glycemic control into cardiovascular risk reduction

According to the results of the current meta-analysis, the odds for a spontaneous clinical pregnancy are almost double (OR 1.97 [95% CI: 1.28, 3.04]

Cai X, She M, Xu M, Chen H, Li J, Chen X, et al